Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow ZTS
Zoetis Inc. (ZTS) Operating cash flow
Zoetis Inc.'s operating cash flow for fiscal 2025 was $2.9B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $2.8B. Over the past ten years it has ranged from $664.0M (fiscal 2015) to $3.0B (fiscal 2024); the current reading is higher than 91% of that period. Zoetis Inc. ranks 3rd of 86 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $2.9B | (1.66%) |
| FY2024 | $3.0B | 25.50% |
| FY2023 | $2.4B | 23.06% |
| FY2022 | $1.9B | (13.60%) |
| FY2021 | $2.2B | 4.09% |
| FY2020 | $2.1B | 18.44% |
| FY2019 | $1.8B | 0.28% |
| FY2018 | $1.8B | 32.99% |
| FY2017 | $1.3B | 88.78% |
| FY2016 | $713.0M | 7.38% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $655.0M | 63.34% |
| Mar 2026 | $401.0M | (55.10%) |
| Dec 2025 | $893.0M | 0.22% |
| Sep 2025 | $891.0M | 47.27% |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $11.1B |
| HLN Haleon PLC Sponsored ADR compare | $4.8B |
| ZTS Zoetis Inc. | $2.8B |
| VTRS Viatris Inc. compare | $2.3B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.9B |
| UTHR United Therapeutics Corporation compare | $1.7B |
| NBIX Neurocrine Biosciences, Inc. compare | $898.1M |
| ELAN Elanco Animal Health Incorporated compare | $617.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $426.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement